Effect of irbesartan versus atenolol on left ventricular mass and voltage: Results of the cardiovascular irbesartan project

Hypertension

Volumn 44, Issue 1, 2004, Pages 61-66

  Schneider, Markus P ^a   Klingbeil, Arnfried U ^a   Delles, Christian ^a   Ludwig, Malte ^b   Kolloch, Rainer E ^c   Krekler, Michael ^a   Stumpe, Klaus O ^b   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Department of Medicine   (Germany)

Author keywords

Drug therapy; Echocardiography; Electrocardiography; Hypertension, essential; Hypertrophy

Indexed keywords

AMLODIPINE; ATENOLOL; HYDROCHLOROTHIAZIDE; IRBESARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; ESSENTIAL HYPERTENSION; FEMALE; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BIPHENYL COMPOUNDS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; TETRAZOLES;

EID: 3042628521     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000133249.28773.d7     Document Type: Article

References (24)

1. Sundström J, Lind L, Arnlow J, Zethelius B, Andrén B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation. 2001;103:2346-2351.
2. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically detected left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
4. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35:580-586.
5. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, Solinas P, Gorini M, Maggioni AP. Left ventricular mass and cardiovascular mortality in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001;38:1829-1835.
6. DeSimone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension. The MAVI study. Hypertension. 2002;40:470-476.
7. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:45-54.
8. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens. 2002;15:1021-1028.
9. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens. 2003;16:895-899.
10. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104:1615-1621.
11. Neaton JD, Grimm RH Jr., Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberg JA, McDonald R, Lewis CE, Liebson PR. Treatment of Mild Hypertension Study: final results. JAMA. 1993; 270:713-724.
12. Schmieder RE, Erdmann J, Delles C, Jacobi J, Fleck E, Hilgers K, Regitz-Zagrosek V. Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol. 2001;37:175-182.
13. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, Miller DH, Reis G, Alderman MH, Laragh JH. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol. 1984;4:1222-1230.
14. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161-186.
15. Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, Chaudhary BS, Phillips MC. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol. 1985;6:572-580.
16. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75:565-572.
17. Molloy TJ, Okin PM, Devereux RB, Kligfield P. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol. 1992;20:1180-1186.
18. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
19. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelmann JM, Dahlöf B. Regression of electrocardiographic: left ventricular hypertrophy by losartan versus atenolol. Circulation. 2003;108:686-690.
20. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou B, Rokkedal J, Dahlöf B. Regression of hypertensive left ventricular hypertrophy: treatment effects and prognostic implications in the LIFE trial. J Hypertens 2002; 20: Abstract 014.
21. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R, Nyström F, Öhman KP, Osbakken MD, Östergren J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19:1167-1176.
22. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with -essential hypertension. Circulation. 1998;98:2037-2042.
23. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized trial. Circulation. 2003;106: 331-336.
24. Moreno I, Caballero R, Gonzales T, Arias C, Valenzuela C, Iriepa I, Galvez E, Tamargo J, Delpon E. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther. 2003;304:862-873.